Smithers supports the development of large-molecule therapeutics from discovery through phase IV, with expertise in bioassays and ultra-sensitivity ligand-binding assays. The services focus on development, validation and sample analysis for PK/TK, ADA, bioassays and fit-for purpose biomarker studies. Smithers supports biologics/monoclonal & polyclonal antibodies/bi-specific antibodies/CAR-T/TCR/biosimilars and biobetters.

Smithers supports the bioanalytical development of a wide range of therapeutics including CAR-T/TCR and other cellular therapeutics, monoclonal and bi-specific antibodies, fusion proteins, biosimilars/biobetters, among many other large-molecule drugs. We operate as a full service GLP/GCP and CLIA contract research organization.